Combination therapies show improved progression-free survival in advanced renal cell carcinoma
In short: A phase 3 trial of 1,069 patients with advanced renal cell carcinoma found that combining lenvatinib with either pembrolizumab or everolimus extended the time before the disease progressed compared to the standard treatment, sunitinib. Specifically, the lenvatinib and pembrolizumab combination showed the most significant improvements in both progression-free survival and overall survival.
The study compared three different treatment regimens to determine which was most effective for patients who had not received previous systemic therapy. While both new combinations outperformed sunitinib in delaying disease progression, only the lenvatinib plus pembrolizumab group showed a statistically significant increase in overall survival.
The trial was a randomized controlled study, which provides high-quality evidence for these associations. However, the researchers noted that both new combinations were associated with high rates of severe adverse events, including hypertension and diarrhea, in a large majority of participants.
Why it matters: New drug combinations can significantly delay disease progression in advanced kidney cancer, though they carry risks of significant side effects.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Motzer et al. (2021). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-combination-therapies-show-improved-progression-free-surviva.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
